The use and therapeutic drug monitoring of teicoplanin in the UK

Clinical Microbiology and Infection

Volumn 10, Issue 1, 2004, Pages 62-69

  Darley, Elizabeth S R ^a   MacGowan, A P ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Bacteraemia; Drug monitoring; Glycopeptides; Staphylococcus aureus; Teicoplanin; Therapy

Indexed keywords

METICILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; CELLULITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MONITORING; DRUG USE; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NEPHROTOXICITY; OSTEOMYELITIS; PRIORITY JOURNAL; QUESTIONNAIRE; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0942277536     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00747.x     Document Type: Article

References (35)

1. Leport C, Perronne C, Massip P et al. Evaluation of teicoplanin for treatment of endocarditis caused by Gram-positive cocci in 20 patients. Antimicrob Agents Chemother 1989; 33: 871-876.
2. Pittet D, Harding I. Infective endocarditis and glycopeptides. J Infect 1998; 37: 127-135.
3. Greenberg RN. Treatment of bone, joint and vascular-access-associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392-2397.
4. Harding I, MacGowan AP, White LO, Darley ESR, Reed V. Teicoplanin therapy for S. aureus septicaemia: relationship between pre-dose serum concentrations and outcome. J Antimicrob Chemother 2000; 45: 835-841.
5. MacGowan A, White L, Reeves D, Harding I. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1996; 2: 197-208.
6. Wilson APR, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4(suppl 1): S1-S30.
7. Steer JA, Papini RPG, Wilson APR et al. Pharmacokinetics of a single dose of teicoplanin in burn patients. J Antimicrob Chemother 1996; 37: 545-553.
8. Bailey EM, Ryback MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991; 35: 1089-1092.
9. Darley ESR, MacGowan AP, White LO. The use and therapeutic drug monitoring (TDM) of teicoplanin in the UK. Clin Microbiol Infect 2000; 6(suppl 1): 205.
10. Gilbert DN, Wood CA, Kimbrough RC. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with S. aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
11. Nathwani D, Reid TMS, Gould IM, Golder D, Smith CC, Douglas JG. An open study of teicoplanin in the treatment of Gram-positive infections. J Chemother 1991; 3: 315-320.
12. Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria. J Antimicrob Chemother 1993; 31: 755-766.
13. Davey PG, South R, Malek M. Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 623-633.
14. Davey PG, Rowley DR, Phillips GA. Teicoplanin-home therapy for prosthetic joint infections. Eur J Surg 1992; 567(suppl): 23-25.
15. Graninger W, Wenish C, Wiesinger E, Menschik M, Karimi J, Presterl E. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995; 14: 643-647.
16. Ketley NJ, Kelsey SM, Newland AC. Teicoplanin and oral ciprofloxacin as outpatient treatment of infective episodes in patients with indwelling central venous catheters and haematological malignancy. Clin Lab Haematol 1995; 17: 71-74.
17. South R. Retrospective study of teicoplanin as home continuation of hospital-initiated therapy. Int J Antimicrob Agents 1998; 9: 219-225.
18. Charbonneau P, Harding I, Garaud JJ, Aubertin J, Brunet F, Domart Y. Teicoplanin: a well tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Med 1994; 20: S35-S42.
19. Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991; 27(suppl B): 69-73.
20. Lewis P, Garaud J-J, Parenti F. A multicentre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria. J Antimicrob Chemother 1988; 21(suppl A): 61-67.
21. Cantú TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-543.
22. Wood M. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37: 209-222.
23. British Society for Antimicrobial Chemotherapy. Breakpoints in in-vitro antibiotic sensitivity testing. Report by a Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 1988; 21: 701-710.
24. Ravizzola G, Pirali F, Foresti I, Turano I. Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against Gram-positive cocci. Drugs Exp Clin Res 1987; 13: 225-229.
25. Ryback MJ, Lerner SA, Levine DP et al. Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991; 35: 696-700.
26. Bonati M, Traina GL, Villa G et al. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacol 1987; 12: 292-301.
27. Grüneberg RN, Antunes F, Chambers HE et al. The role of glycopeptide antibiotics in the treatment of infective endocarditis. Int J Antimicrob Agents 1999; 12: 191-198.
28. Le Frock JL, Ristuccia AM, Ristuccia PA et al. Teicoplanin in the treatment of bone and joint infections. Eur J Surg 1992; 567(suppl): 9-13.
29. Wilson APR, Grüneberg RN. Use of teicoplanin in community medicine. Eur J Clin Infect Dis 1994; 13: 701-710.
30. MacGowan AP, McMullin CM, White LO, Reeves DS, Davis E, Speller DCE. Serum monitoring of teicoplanin. J Antimicrob Chemother 1992; 30: 399-402.
31. Wilson APR, Grüneberg RN, Neu H. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993; 32: 792-796.
32. Working Party of the British Society for Antimicrobial Chemotherapy. Antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis. Heart 1998; 79: 207-210.
33. Waldvogel FA. S. aureus (including toxic shock syndrome). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 4th edn. New York: Churchill Livingstone, 1995; 1767-1768.
34. Carver P, Nightingale C, Quintiliani R, Sweeney K, Stevens RC, Maderazo E. Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob Agents Chemother 1989; 33: 82-86.
35. Outman W, Nightingale C, Sweeney K, Quintiliani R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother 1990; 34: 2114-2117.